SG Americas Securities
MRKR icon

SG Americas Securities’s Marker Therapeutics MRKR Stock Holding History

SG Americas Securities’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,601
Closed -$33K – 3172
2020
Q2 		$33K Buy
+1,601
New +$35K ﹤0.01% 3577

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

SG Americas Securities's MRKR Position: Q3 2020 in Review

SG Americas Securities sold out of Marker Therapeutics (MRKR) in Q3 2020, closing a stake of 1,601 shares — an estimated $33K sold.

SG Americas Securities first reported a position in MRKR in Q2 2020 and held it in 1 quarter. The position peaked at $33K in Q2 2020. 58 funds tracked by Wall St. Rank hold MRKR as of Q3 2020.

  • SG Americas Securities reported no remaining Marker Therapeutics position as of Q3 2020 after selling out during the quarter.
  • SG Americas Securities sold 1,601 Marker Therapeutics shares in Q3 2020, an estimated $33K.
  • SG Americas Securities first reported a position in Marker Therapeutics in Q2 2020 and held it in 1 quarter.
  • SG Americas Securities's Marker Therapeutics position peaked at $33K in Q2 2020.
  • 58 funds tracked by Wall St. Rank held Marker Therapeutics as of Q3 2020.

Based on SG Americas Securities's 13F filing for Q3 2020, filed 9 Nov 2020.